ABSTRACT
Hepatocellular carcinoma is characterized by a high rate of incidence,along with significant likelihood of postoperative recurrence and metastatic,whereas its underlying mechanism remains considerably unclear.The overexpression of Aspartyl/Asparaginyl beta-hydroxylase (ASPH,AAH) was initially found in hepatocellular carcinoma and cholangiocarcinoma,signifying its involving in multiple biological behaviors of hepatocellular carcinoma.Here we review recent advances on ASPH in hepatocellular carcinoma,aiming to provide a new theoretical basis for its treatment prospectively.
ABSTRACT
Aspartyl-(asparaginyl) β-hydroxylase (AAH) is a type 2 transmembrane protein and a member of the α-ketoglutarate-dependent dioxygenase family of proteins.AAH catalyzes hydroxylation of specific aspartyl and asparaginyl residues in epidermal growth factor-like domains of proteins.Overexpression of AAH is found in many types of cancer tissues,however,AAH expression is found only in normal placenta and paranephros tissues.AAH can translocate to cell membrane from endoplasmic reticulum membrane when it is overexpressed in cancer cell,which hydroxylate proteins such as Notch,Jagged,and cellular adhesion molecules that regulate cell migration and invasion.AAH is a potential biomarker for cancer diagnosis.